Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Cancer Immunol Res. 2015 Dec 23;4(3):204–214. doi: 10.1158/2326-6066.CIR-15-0188

Figure 1.

Figure 1

Quantitative RT-PCR analysis of expression of mutated KRAS mRNA in pancreatic tumor lines. (A) cDNAs from five KRAS G12V-positive tumor lines and two KRAS G12V-negative tumor lines were synthesized for expression analysis. Mutation status was verified by sequencing of genomic DNA shown in table S1. Primers specific for KRAS gene regardless of mutation status (designated as “Reference”), or for mutated KRAS G12V (designated as “G12V”) were used in the analysis. Results are presented relative to ACTB mRNA (encoding β-actin). (B) Similar analysis of KRAS expression of five KRAS G12D-positive tumor lines and three KRAS G12D-negative tumor lines.